Antimicrobial Doses in Continuous Renal Replacement Therapy: A Comparison of Dosing StrategiesReport as inadecuate




Antimicrobial Doses in Continuous Renal Replacement Therapy: A Comparison of Dosing Strategies - Download this document for free, or read online. Document in PDF available to download.

Critical Care Research and Practice - Volume 2016 2016, Article ID 3235765, 6 pages -

Research ArticleClinical Pharmacy Department, University of Michigan College of Pharmacy, Ann Arbor, MI 48109, USA

Received 23 December 2015; Accepted 9 May 2016

Academic Editor: Robert Boots

Copyright © 2016 Anna P. Kempke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. Drug dose recommendations are not well defined in patients undergoing continuous renal replacement therapy CRRT due to limited published data. Several guidelines and pharmacokinetic equations have been proposed as tools for CRRT drug dosing. Dose recommendations derived from these methods have yet to be compared or prospectively evaluated. Methods. A literature search of PubMed, Micromedex, and Embase was conducted for 40 drugs commonly used in the ICU to gather pharmacokinetic data acquired from patients with acute and chronic kidney disease as well as healthy volunteers. These data and that obtained from drug package inserts were gathered for use in three published CRRT drug dosing equations. Doses calculated for a model patient using each method were compared to doses suggested in a commonly used dosing text. Results. Full pharmacokinetic data was available for 18, 31, and 40 agents using acute kidney injury, end stage renal disease, and normal patient data, respectively. On average, calculated doses differed by 30% or more from the doses recommended by the renal dosing text for >50% of the medications. Conclusion. Wide variability in dose recommendations for patients undergoing CRRT exists when these equations are used. Alternate, validated dosing methods need to be developed for this at-risk patient population.





Author: Anna P. Kempke, Abbie S. Leino, Farzad Daneshvar, John Andrew Lee, and Bruce A. Mueller

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents